Traditionally, cancer studies have primarily focused on mutations that activate growth or survival pathways in susceptible pre-neoplastic/neoplastic cells. However, recent research has revealed a critical role for nonneoplastic cells within the tumor microenvironment in the process of cancer formation and progression. In addition, the existence of regional and developmental variations in susceptible cell types and supportive microenvironments support a model of tumorigenesis in which the dynamic symbiotic relationship between neoplastic and non-neoplastic cell types dictate where and when cancers form and grow. In this review, we highlight advances in neurofibromatosis type 1 (NF1) genetically engineered mouse brain tumor (glioma) modeling to reveal how cellular and molecular heterogeneity in both the pre-neoplastic/ neoplastic and non-neoplastic cellular compartments contribute to gliomagenesis and glioma growth.
Introduction
Based on seminal studies in colon cancer, tumor development is often thought to result entirely from an accumulation of acquired genetic changes that allow a cell to escape the constraints that normally control cell proliferation, death and migration. These constraints are typically provided by the local microenvironment (stroma) in the form of growth factors, chemokines and extracellular matrix (ECM) molecules. The presence of each type of stromal molecule instructs the cell to divide, differentiate, die or migrate, and thus regulates the orderly behavior of that cell within its natural tissue environment. However, traditional models of tumorigenesis have largely focused on identifying cancercausing genetic changes present in the neoplastic cells without considering the local microenvironment. In these models, tumor formation is envisioned as a stochastic series of events that allow neoplastic cells, through a process of natural selection, to predominate and culminate in cancer. Although these models have been incredibly instructive, they fail to account for the spatial and temporal patterns of tumor formation, and do not fully explain several unique features of pediatric brain tumors.
In this review, we will explore brain tumor formation as a developmental abnormality involving interactions between neoplastic and non-neoplastic cells, in which molecular alterations in non-neoplastic cells not only affect tumor proliferation and maintenance, but also influence the propensity for tumor initiation and formation through the co-evolution of a permissive microenvironment. Both before and during tumor development, non-neoplastic and neoplastic species change the cellular and molecular composition of their local milieu by recruiting new cell types, activating existing cell types and modifying the regional expression profile of specific molecules (for example, growth factors, cytokines and ECM proteins). The cumulative effect of these changes over time creates a permissive microenvironment that provides the necessary substrate for the expansion of preneoplastic and neoplastic cells during the process of oncogenesis and continued tumor growth.
Traditional models of oncogenesis
The multistep model of tumorigenesis was initially proposed by Vogelstein and colleagues for colorectal cancer, based on the identification of a series of genetic mutations arising in colorectal cancers at various stages of malignant progression (Fearon and Vogelstein, 1990) . The observation that some genetic changes occurred at the earliest stages of oncogenesis (epithelial hyperplasia) whereas others were only detected in more malignant cancers suggested a model in which the orderly acquisition of cancer-causing genetic changes explained the progression from the pre-neoplastic lesion (polyp) to advanced metastatic colon cancer (Figure 1 ). However, it is more likely that it is the complement of genetic changes, rather than the chronological order of acquisition, that drives the process of tumorigenesis and malignant progression.
Weinberg and colleagues experimentally defined a series of six hallmark changes necessary for the progression from cancer initiation to tissue invasion and metastasis. These include growth signal selfsufficiency, antigrowth signal insensitivity, apoptosis evasion, limitless replicative potential, angiogenesis, and tissue invasion and metastasis (Hanahan and Weinberg, 2000) . In their model, the introduction of human telomerase reverse transcriptase, oncogenic H-Ras and simian virus 40 large T-antigen in normal human kidney epithelial and fibroblast cells conferred limitless replicative potential, growth signal self-sufficiency and apoptosis evasion, respectively, and resulted in oncogenic transformation (Hahn et al., 1999) . Similarly, this collection of genetic alterations was also shown to be sufficient for the transformation of normal astrocytes to malignant astrocytomas (Sonoda et al., 2001) .
Although these changes were introduced into a susceptible pre-neoplastic cell, it should be recognized that these hallmark properties reflect escape from the normal constraints provided by the local environment. In this regard, HRAS mutation results in constitutive activation of pro-proliferative and antiapoptotic pathways that normally would be governed by extracellular ligands binding to their cognate receptor tyrosine kinases. The presence of a constitutively active H-Ras molecule obviates the need for these extracellular growth/survival factors by providing an equivalent intracellular proliferative or survival signal. Similarly, mutational loss of the Deleted in Colorectal Carcinomas (DCC) gene during colorectal cancer formation is thought to reduce normal cell-cell and cell-ECM adhesions (Fearon and Vogelstein, 1990) , whereas TP53 mutation results in loss of p53-mediated cell cycle arrest and apoptosis (Baker et al., 1989; Vousden, 2002) . These tumor suppressor gene inactivation events provide escape from the growth and survival constraints normally provided by the local microenvironment.
Incorporating the tumor microenvironment
The concept that oncogenic changes in a pre-neoplastic cell type are necessary, but not completely sufficient, for tumorigenesis is highlighted by the differential patterns of metastatic colonization. For example, B16 melanoma cells injected into mice only form tumors in pulmonary or ovarian tissue, but not in renal tissue (Hart and Fidler, 1980) . Furthermore, human breast cancer cell lines injected into the mammary glands of naı¨ve mice widely disseminate, but metastatic tumors only develop in the lungs and lymph nodes, even though dormant cells could be recovered from organs without metastasis (Suzuki et al., 2006) . These findings raise the intriguing possibility that determinants beyond the neoplastic cell are critical for progression.
The microenvironment of a solid tumor is composed of numerous non-neoplastic cell types, such as fibroblasts, infiltrating and resident immune cells, and recruited macrophages and mast cells. These cell types, although not tumorigenic, have the capacity to produce growth/survival factors, chemokines, ECM and angiogenic molecules that change the local milieu in which these pre-neoplastic/neoplastic cells live. The specific composition of this microenvironment further varies depending on the developmental age, tissue type and stage of malignant progression (Egeblad et al., 2005; Coussens and Werb, 2010; Rozario and DeSimone, 2010) .
Some of the first studies to demonstrate the influence of the microenvironment on tumorigenesis examined the relationship between fibroblasts and epithelial cells during wound healing (Gabbiani et al., 1972 (Gabbiani et al., , 1978 and breast cancer progression (Tremblay, 1979) . Cancer-associated fibroblasts, or myofibroblasts, exhibit embryonic-like migratory properties (Schor et al., 1988) and stimulate prostate tumor progression (Olumi et al., 1999) as well as support the initiation and progression of breast cancer (Barcellos-Hoff and Ravani, 2000) . Matrix metalloproteinases secreted from these cancer-associated fibroblasts change the ECM and alter the signal transduction responses of epithelial cells to growth factors, thus forming a reactive stroma that enhances tumorigenesis (Lee and Streuli, 1999; Sternlicht et al., 1999) . One of the key signaling molecules produced by cancer-associated fibroblasts is transforming growth factor-b (TGF-b): TGF-b activates fibroblasts to increase ECM formation (Keski-Oja et al., 1988) and promotes epithelial cell and fibroblast proliferation, depending upon the complement of growth factors present in the local microenvironment (Roberts et al., 1985) . Collectively, these studies support a model of tumorigenesis in which TGF-b signaling creates a permissive stromal state for epithelial cancer initiation and progression (Bhowmick et al., 2004; Cheng et al., 2005) .
Other stromal components, including immune system cells, also can participate in the process of tumor formation. In the initial stages of tumor formation, recruited immune cells may suppress tumor formation through 'immunoediting' (Dighe et al., 1994; Dunn et al., 2002) , which represents a process of cancer cell elimination by immune system cells. Following this initial period of elimination, some tumor cells will acquire the ability to escape immune recognition and exist in a state of dynamic equilibrium with the immune Figure 1 Hallmark changes acquired during colorectal cancer progression. A series of genetic mutations enable cancer cells to escape from the normal local microenvironment constraints on growth and survival. Among these changes, mutations affecting the adenomatosis polyposis coli (APC) gene facilitate the progression to dysplasia, while KRAS and TP53 alterations are implicated in the development of adenoma and carcinoma, respectively. Mutations of the deleted in colorectal cancer (DCC) gene promote evasion of apoptosis and invasion in late adenoma. Mutations in the transforming growth factor-beta (TGF-b) signaling pathway as well as other genetic changes that alter adhesion to ECM components, such as overexpression of matrix metalloproteinases that degrade ECM substrates, contribute to invasion and metastasis.
system (Shankaran et al., 2001) . Eventually, these tumor cells will proliferate and expand.
Similar to fibroblasts, mast cells and macrophages can also be recruited to the tumor by chemotactic factors (Dabbous et al., 1986; Graves et al., 1989) . Recruited mast cells activate fibroblast collagen synthesis and induce angiogenesis through the secretion of the mast cell serine proteases monocyte chemoattractant protein-4 and monocyte chemoattractant protein-6 (Coussens et al., 1999) . Mast cells can also increase ECM degradation in rodent mammary carcinomas, thereby facilitating tissue invasion and metastasis (Dabbous et al., 1986) . Similarly, recruited macrophages can also degrade elastin, glycoproteins and collagen to promote invasion through secreted proteinases (Werb et al., 1980; Coussens et al., 2000) and regulate angiogenesis and metastasis through production of proangiogenic factors (Lin et al., 2006; Pollard, 2008) .
The brain as a specialized ecosystem
Similar to tumors in other organs, brain tumors are composed of an evolving ecological community composed of non-neoplastic and pre-neoplastic/neoplastic cells. However, the normal brain is a specialized niche that lacks fibroblasts and is essentially lymphocyte free, both of which are key players in the microenvironment of other solid cancers. The environment of the brain consists of blood vessels, ECM, microglia, pericytes, oligodendrocytes, progenitor cells, astrocytes and neurons. As the normal brain develops and matures, these cell types and the signals they elaborate vary over time and in different brain regions.
The spatial and temporal pattern of brain tumor formation is illustrated by the age of onset and location of glial cell malignancies (Louis et al., 2007) . In children, gliomas predominate in infratentorial locations, including the optic pathway, brainstem and cerebellum, whereas in adults, gliomas are more commonly found in supratentorial regions, such as the cerebral hemispheres. Even within the brainstem, gliomas tend to form in the pons (Ueoka et al., 2009) . Moreover, the histological grade of gliomas differs in children compared with adults. World Health Organization grade I pilocytic astrocytomas are more frequent in children, whereas higher grade malignancies are found in adults. Interestingly, pilocytic astrocytomas rarely progress to high-grade glial cancers compared with the progressive nature of adult grade II gliomas. These unique patterns of gliomagenesis could reflect differences in susceptible pre-neoplastic cell types, causative oncogenic mutations and/or unique features of the microenvironment in these different brain locations.
Insights into the critical interplay between preneoplastic/neoplastic cells and non-neoplastic cell types in the evolving tumor microenvironment have derived from studies of inherited cancer syndromes. Individuals with these cancer pre-disposition syndromes are born with one mutated copy of a tumor suppressor gene in all cells throughout their bodies. For example, in familial retinoblastoma (RB), patients are heterozygous for an inactivating mutation in the retinoblastoma tumor suppressor gene. RB tumors develop following bi-allelic inactivation of the RB gene (Cavenee et al., 1983; Dryja et al., 1984) . As children born with a germline RB mutation require only one additional genetic alteration, the loss of the one remaining functional allele, the incidence of RB tumor formation is much higher and occurs at an earlier age than observed in the general population, where both RB alleles must be inactivated in the same cell for tumors to develop (Knudson, 1971 ).
Neurofibromatosis-1 as a model system
The most common of the inherited tumor pre-disposition syndromes in which affected children develop brain tumors (gliomas) is neurofibromatosis type 1 (NF1). This disorder is characterized by the presence of optic pathway gliomas, neurofibromas (peripheral nerve sheath tumors), as well as pigmentary changes, such as cafe´-au-lait macules, skinfold freckling, and Lisch nodules . There are several features of NF1-associated glioma formation and growth that merit further discussion: First, while the vast majority of patients with NF1 form peripheral nerve sheath tumors (Huson et al., 1988) , only 15-20% of children with NF1 develop brain tumors. Second, gliomas predominate in the optic pathway as opposed to the cerebellum, where they more commonly arise in the general population (Listernick et al., 1995) . Third, NF1-associated optic gliomas arise at a younger age (mean ¼ 4.5-5.8 years) than in the general population (mean ¼ 5.1-12 years) (Stern et al., 1980; Listernick et al., 1989 Listernick et al., , 1994 Singhal et al., 2002; Thiagalingam et al., 2004) . Fourth, unlike their sporadic counterparts, NF1-associated optic gliomas are less likely to progress and require treatment (Listernick et al., 1997) . This unique spatial and temporal pattern of gliomagenesis suggests that additional factors, including susceptible cell types, permissive microenvironments and genomic modifiers, may dictate when and where gliomas form in individuals with NF1.
Recapitulating NF1-associated brain tumors in Nf1 genetically engineered mice Genetically engineered mouse (GEM) models are powerful tools to study the molecular mechanisms and cellular origins of brain tumors. In genetic pre-disposition models, GEM provides unprecedented opportunities to define the developmental changes in critical cell types throughout the natural history of tumor initiation, proliferation and progression. In this regard, mice engineered to lack Nf1 gene expression in glial fibrillary acidic protein-positive glial progenitor cells did not develop brain tumors (astrocytomas or gliomas) in vivo, although there was increased growth in Nf1-deficient astrocytes (Bajenaru et al., 2002) . To more accurately model the NF1 human condition, mice heterozygous for an inactivating Nf1 mutation (Nf1 þ /À ) in every cell in their bodies were designed to also lack Nf1 gene expression (Nf1 À/À ) in glial progenitors (Bajenaru et al., 2003; Zhu et al., 2005) . These mice developed low-grade optic gliomas, recapitulating the predominance of optic pathway gliomas seen in NF1 patients (Bajenaru et al., 2005) . The fact that a brain microenvironment composed of Nf1 þ /À cells is required for gliomagenesis and that the combination of Nf1 loss in glial progenitors and stromal Nf1 heterozygosity results in gliomas restricted to the optic pathway supports the use of Nf1 GEM strains as tractable models to illustrate the complex interplay between pre-neoplastic cells, non-neoplastic cells and genomics in gliomagenesis.
Susceptible cell type
As described previously, the preferential spatial pattern of NF1-associated gliomagenesis raises the possibility that glial cell types in different brain regions may be differentially responsive to NF1 gene inactivation. Evidence for this diversity derives from studies that demonstrate unique molecular signatures from glial tumors, as well as normal astrocytes and progenitor cells arising from different brain regions (Taylor et al., 2005; Sharma et al., 2007) . One impact of this molecular diversity is variation in the expression levels of specific tumor suppressor genes. For example, Nf1 mRNA and protein expression was significantly reduced in astrocytes from the neocortex compared with astrocytes from the optic nerve, cerebellum, or brainstem, such that Nf1 inactivation in the neocortical astrocytes did not result in increased proliferation (Yeh et al., 2009) . In addition, similar brain region-specific effects of Nf1 inactivation have recently been reported for neural stem cells (Lee et al., 2010) . Neural stem cells from the brainstem, but not the cortex, exhibit increased proliferation and glial cell differentiation following Nf1 inactivation in vitro and in vivo. Collectively, these findings support the notion that not all neural stem cell or glial populations will proliferate in response to Nf1 inactivation, and that cellular heterogeneity may in part contribute to the spatial pattern of gliomagenesis in this inherited cancer syndrome.
An additional level of heterogeneity is conferred by the differential effects of NF1 protein, neurofibromin, on downstream growth control pathways (Figure 2 ). Sequence analysis of the predicted NF1 protein sequence revealed that it contains a small domain with striking similarity to the catalytic segment of a family of proteins termed GTPase activating proteins. Neurofibromin was subsequently shown to be a Ras-GTPase activating protein, accelerating the conversion of active GTPbound Ras to inactive GDP-bound Ras (Ballester et al., 1990) , such that loss of neurofibromin expression results in increased Ras activity and increased Ras-driven cell proliferation (Basu et al., 1992 ; DeClue et al., 1992).
However, neurofibromin may not negatively regulate all Ras isoforms in every cell type (Walsh and Bar-Sagi, 2001; Ehrhardt et al., 2004) . For instance, only the K-Ras isoform is activated in Nf1-deficient astrocytes despite equal expression of all three Ras isoforms (Dasgupta et al., 2005a) . Similar findings have also been reported for other Nf1-deficient cell types (Khalaf et al., 2007; Morgan et al., 2007) . This heterogeneity will need to be considered when selecting effective drugs for NF1-associated cancer treatment. This is well illustrated by the poor clinical response of NF1-associated peripheral nerve sheath tumors to farnesyltransferase inhibitors that inhibit Ras (Widemann et al., 2006) , as these drugs preferentially inhibit H-Ras, rather than K-Ras (Prendergast and Rane, 2001) .
Moreover, the Ras downstream signaling pathways that transduce this proliferative message vary between cell types. Proliferation or survival is mediated through Ras/MAPK signaling in Nf1-deficient or heterozygous mast cells (Khalaf et al., 2007; McDaniel et al., 2008) and vascular smooth muscles Xu et al., 2007) . Multiple pathways contribute to increased osteoclast activity and gain of function (Yang et al., 2006; Yan et al., 2008; Li et al., 2009) as well as abnormal myeloid cell survival and proliferation (Bollag et al., 1996; Donovan et al., 2002) . However, Nf1-deficient cell growth regulation is dependent on Ras activation of the mammalian target of rapamycin (mTOR) pathway in astrocytes (Dasgupta et al., 2005b; Sandsmark et al., 2007) and Schwann cells (Johannessen et al., 2005; Johansson et al., 2008) . In astrocytes, neurofibromin loss leads to mTOR-dependent increases in cell proliferation, which reflect mTOR regulation of Rac1 (Sandsmark et al., 2007) and STAT3 (Banerjee et al., 2010) . These differences have profound implications with respect to therapeutic drug design and support the use of rapamycin, an immunosuppressant drug, to specifically inhibit the mTOR pathway in Nf1-deficient gliomas (Hegedus et al., 2008) and Schwann cell malignancies (Johansson et al., 2008) , and MEK inhibitors for other NF1-associated tumor types.
Tumor microenvironment
Although the heterogeneity of cell types in different brain regions partly accounts for the patterns of gliomagenesis seen in NF1 patients, additional spatial and temporal signals from the tumor microenvironment are likely required to fully explain the unique features of glioma development and growth in NF1 (Figure 3 ). Studies using Nf1 GEM strains have been particularly instructive for identifying specific stromal cell types and molecules that provide the optimal substrate for preneoplastic cell proliferation and gliomagenesis. Non-neoplastic stromal cells function in part to provide a permissive microenvironment for tumorigenesis through the release of factors that expand the preneoplastic/neoplastic cell populations (gliomagens) as well as promote the formation of a local milieu rich in other non-neoplastic cell types (stromagens). This is facilitated by both pre-neoplastic/neoplastic cells and non-neoplastic cells that can produce stromagens to attract other stromal cell types, such as chemokine recruitment of microglia or endothelial cells to the region of a developing tumor. These recruited stromal cells elaborate molecules that promote pre-neoplastic/ neoplastic glial cell proliferation, survival and invasion. Thus, during tumor evolution, there is a dynamic relationship established between neoplastic and nonneoplastic cells through the elaboration of stromagens and gliomagens that together facilitate tumor formation and subsequently promote tumor maintenance and progression.
Stromal determinants of glioma formation and growth
Microglia are one of the key cell types in the tumor surround that provide a permissive environment for tumorigenesis, as they can produce both gliomagens and stromagens. Tumor-associated microglia constitute the main population of brain immune cells (Graeber et al., 2002) and are important for monitoring their local environment, regulating function and apoptosis, and secreting proinflammatory cytokines (Banati et al., 1993; Elkabes et al., 1996; Marı´n-Teva et al., 2004; Roumier et al., 2004) . These resident brain immune system mononuclear cells can be recruited by glioma tumors cells to the local tumor microenvironment by vascular Figure 3 Co-evolution of neoplastic and non-neoplastic cells in gliomas. Loss of heterozygosity (grey to red) of critical tumor suppressor genes, such as the NF1 gene, in susceptible astroglial cell types is an initial step in gliomagenesis. These NF1-deficient astrocytes release factors (stromagens) to recruit or activate microglia as well as other stromal cells types (for example, endothelial cells and non-neoplastic astrocytes) to create a supportive microenvironment. Stromal cells elaborate gliomagens that promote the growth of these pre-neoplastic/neoplastic astroglia. A dynamic relationship forms between the pre-neoplastic/ neoplastic and non-neoplastic stromal cell populations through stromagen and gliomagens release, which together facilitate tumorigenesis, tumor maintenance and glioma progression. endothelial growth factor (Forstreuter et al., 2002; Kerber et al., 2008) , hepatocyte growth factor (Badie et al., 1999; Kunkel et al., 2001) , monocyte chemoattractant protein-1 (Martinet et al., 1992; Leung et al., 1997) and the chemokine CX3CL1 (fractalkine) through activation of the CX3CR1 receptor (Held-Feindt et al., 2010) . Monocyte chemoattractant protein-1 can also increase the surface expression of CX3CR1 on microglia (Green et al., 2006) , thus providing amplification circuits for further microglia recruitment. Once present in the tumor microenvironment, microglia can secrete inflammatory molecules such as interleukin-10 and interleukin-6 (Wagner et al., 1999; Williams et al., 2000) . Elevated levels of these two interleukins are correlated with the degree of malignancy in gliomas (Huettner et al., 1995; Sasaki et al., 2001) as well as increased proliferation and migration of glioma cell lines (Huettner et al., 1997; Wang et al., 2009) . In particular, interleukin-6 ablation prevents tumor formation in a v-src-induced model of gliomagenesis (Weissenberger et al., 2004) .
Moreover, it should be appreciated that microglia, like astrocytes, may have different properties depending on their local microenvironment. Cerebral microglial expression of CD40 is lower than in cerebellar microglia, and CXCR3, a chemokine that regulates cell migration, is higher in cerebral microglia than in those from the hippocampus (de Haas et al., 2008) . These observations suggest that different brain regions harbor unique populations of microglia that can differentially contribute to the spatial and temporal patterns of glioma formation and growth.
Using an Nf1 optic glioma GEM model, increased numbers of microglia were found along the optic nerve before histologically and radiographically obvious glioma formation (Bajenaru et al., 2005) . The microglia in these pre-neoplastic optic nerves are Nf1 þ /À resident brain microglia, with increased proliferation, motility and activation compared with their wild-type counterparts Daginakatte et al., 2008) . The importance of microglia to mouse optic glioma proliferation is underscored by two experimental findings: First, microglia inactivation using the minocycline antibiotic results in reduced optic glioma proliferation . Second, Nf1 þ /À microglia have increased activation of the c-Jun kinase signaling pathway, whereas Nf1-deficient astroglial cells have no c-Jun kinase hyperactivation (Daginakatte et al., 2008) . Inhibition of c-Jun kinase activation results in reduced Nf1 þ /À microglia proliferation and motility in vitro, such that inhibition of Nf1 þ /À microglia function with crude c-Jun kinase inhibitors attenuated optic glioma proliferation in vivo.
Determining how Nf1 þ /À brain microglia promote Nf1-deficient glial cell proliferation required the identification of the relevant gliomagens . Two complementary approaches have been applied to date. First, using a microarray strategy, Nf1 þ /À microglia were found to express increased levels of the hyaluronidase-like protein, meningioma-expressed antigen-5 (MGEA5). Cultured media from Nf1 þ /À microglia increased the proliferation of Nf1 À/À astrocytes in vitro, which could be inhibited using crude hyaluronidase inhibitors . The ability of MGEA5 to promote Nf1-deficient astrocyte proliferation reflected MAPK activation, a pathway not previously found to drive Nf1 À/À glial cell growth. Although this pathway may not be a major mitogenic signaling pathway in glial cells, it is possible that MAPK activation cooperates with other stromal signals to increase Nf1 À/À astrocyte growth. A second approach to identifying Nf1 þ /À microglia gliomagens involves the examination of known molecules that regulate signaling pathways controlled by neurofibromin. Previous studies from our laboratory and others have shown that neurofibromin positively regulates cyclic adenosine monophosphate (cAMP) levels (Tong et al., 2002; Dasgupta et al., 2003) in the brain in addition to negatively regulating Ras activity. The regulation of both Ras and cAMP is one of the properties of G-protein-coupled receptors, which suggests that chemokines present in the tumor microenvironment might increase Nf1 À/À astrocyte growth. One of these chemokines, CXCL12, is developmentally and spatially regulated, such that high levels of CXCL12 is found in young mammals along the optic pathway (Warrington et al., 2007) . Moreover, Nf1 þ /À microglia express three times more CXCL12 than their wild-type counterparts.
CXCL12 acts on its receptor, CXCR4, to regulate both cAMP levels and Ras activity (Klein and Rubin, 2004) , and CXCL12 treatment of wild-type astrocytes causes increased cell death through apoptosis (Warrington et al., 2007) . In striking contrast, CXCL12 treatment of Nf1 À/À astrocytes resulted in increased cell survival. The major pro-survival effect of CXCL12 on Nf1-deficient astrocytes is mediated by cAMP. In this regard, restoration of wild-type levels of cAMP by several methods attenuates Nf1 À/À astrocyte survival. This observation prompted a preclinical study to determine whether elevating cAMP in Nf1 optic glioma mice would reduce glioma growth. Although the effects of Rolipram, which blocks phosphodiesterase-4-mediated cAMP degradation, were transient, treatment resulted in attenuated glioma growth (Warrington et al., 2010) .
The finding that CXCL12 expression is one of the key stromal determinants dictating where gliomas form in NF1 raises the intriguing possibility that the pattern of tumorigenesis could be changed by ectopically expressing CXCL12 in regions of the brain where gliomas do not form in Nf1 GEM strains. However, ectopic lentiviral CXCL12 expression in the forebrain of Nf1 optic glioma mice did not induce gliomas with high penetrance (Sun et al., 2010) , arguing against CXCL12 as the only spatial determinant important for NF1-associated gliomagenesis. In contrast, ectopic expression of phosphodiesterase-4 to lower cAMP levels in the forebrain of Nf1 optic glioma mice did lead to glioma formation (Warrington et al., 2010) . Interestingly, there are significant variations in the levels of cAMP in different brain regions, with high levels of cAMP in the forebrain compared with the optic nerve (Warrington et al., 2007 (Warrington et al., , 2010 . Collectively, these findings support the hypothesis that a combination of Nf1 þ /À stromal cell types, permissive cell types and basal signaling levels contribute to the pattern of gliomagenesis in NF1.
The tumor microenvironment impact on non-neoplastic cells
In addition to the effects of the NF1 þ /À microenvironment on gliomagenesis, additional studies using Nf1 GEM strains highlight the impact of NF1 heterozygosity on the response of non-neoplastic cells to tumor formation. Although most children with NF1-associated optic gliomas will not require treatment for progressive visual loss, nearly 50% of children with NF1 and an optic glioma initially present with visual impairment (Listernick et al., 1995) . Using evoked potentials to measure visual function in Nf1 optic glioma mice, reduced potentials were detected early during tumor evolution, suggesting that disrupted relationships between neurons and their associated glial cells may result in abnormal neuronal transmission (Hegedus et al., 2009) . To this end, before the development of a radiographically and histologically evident optic glioma, progressive increases in optic nerve axon calibers were found, followed by axonal swelling and apoptosis in the retinal ganglion cell layer. Further examination revealed that Nf1 þ /À retinal ganglion cell neurons have shorter neurites, growth cones and survival in vitro, such that axon injury or optic glioma formation leads to increased neuronal death (Brown et al., 2010) . Interestingly, unlike peripheral nervous system neurons in which Nf1 loss results in inappropriate cell survival as a consequence of Ras-Akt pathway hyperactivation, reduced neurofibromin expression in central nervous system neurons has the opposite effect that instead results from reduced neurofibromin-mediated cAMP generation. Particularly relevant to future neuroprotective strategies, elevating cAMP using phosphodiesterase-4 inhibitors results in attenuated retinal ganglion neuron death in response to glioma formation in vivo (Brown et al., 2010) .
Importance of the genomic background
One of the unresolved issues in NF1 gliomagenesis revolves around the incomplete penetrance of this tumor phenotype. In contrast to the peripheral nerve sheath tumors (neurofibromas), only 15-20% of children with NF1 develop optic gliomas. This clinical observation suggests that gliomagenesis requires more than a permissive environment and susceptible progenitor cells. As nearly 100% of Nf1 GEM develop optic gliomas when maintained on a C57BL/6 genetic background, and rare mice lacking optic gliomas are almost invariably born with a white coat color, it is highly likely that tumorigenesis is influenced by genomic determinants.
Support for a role for genomic modifiers in NF1-associated gliomagenesis derives from elegant studies by Reilly and associates using a different Nf1 GEM model.
In this system, astrocytomas formed with high frequency in NPCis (Nf1
) mice when the genetic background was C57BL/6J, but only rarely in mice with the 129S4/SvJae background (Reilly et al., 2000 (Reilly et al., , 2004 . This observation suggests that there may be epigenetic or polymorphic differences between these strains that could confer additional resistance or susceptibility to gliomagenesis (Hawes et al., 2007; Dong et al., 2008) .
The existence of modifier loci creates two interesting and clinically relevant opportunities. First, modifier loci could function by changing the expression or function of genes important for glial cell biology or neurofibromin growth regulation. In this way, it is possible that subtle polymorphic changes in genes that encode proteins of the Ras or cAMP regulatory pathways could increase or decrease the effect of neurofibromin loss on glial cell growth. Similarly, polymorphisms that alter chemokine function or microglia activity could likewise attenuate or amplify the impact of NF1 heterozygosity on susceptible cell types in the tumor microenvironment. Finally, it is possible that strain-dependent changes lead to differences in overall neurofibromin expression, which alter the effect of NF1 heterozygosity on non-neoplastic cell function (Pemov et al., 2010) .
Second, the finding of strain differences in glioma susceptibility suggests that genomic polymorphisms might determine which children with NF1 will develop optic gliomas. The identification of single nucleotide polymorphisms predictive of glioma risk would have tremendous impact on the management of children with NF1, and would allow clinicians to stratify children from an early age into clinically relevant subgroups for surveillance and potential treatments.
In addition, there could be other etiologies beyond our current understanding of neurofibromin growth control pathways, microenvironmental determinants, brain region-specific cellular heterogeneity and genomic modifiers that influence how oncogenesis occurs in patients with NF1. Identifying these factors may provide future targets for treatment that are not obvious at this time.
Conclusion
Recent advances in mouse brain tumor modeling support the notion that these cancers represent neurodevelopmental abnormalities. As would be expected, the rules that govern proliferation, apoptosis, differentiation and migration of cells during the process of normal brain formation and maintenance apply to tumors arising in the brain. Cell types and signals that are normally tightly regulated can become de-regulated and co-opted during tumorigenesis, such that these instructive cues become inappropriately active in response to specific genetic mutations.
Although Nf1 inactivation in glial lineage cells is a necessary step in oncogenesis, it must occur in a cell type capable of expanding in response to loss of neurofibromin growth regulation. This capacity is dictated not only by brain location, but also by the developmental stage. Elegant studies by a number of groups have demonstrated a more limited capacity for accelerated growth following Nf1 inactivation in differentiated astrocytes compared with glial progenitor cells (Zhu et al., 2005; Alcantara Llaguno et al., 2009) . Together, these observations establish a regional and developmental context in which bi-allelic Nf1 inactivation will lead to glioma formation.
In addition to Nf1 loss in a susceptible cell type, environmental factors are critical determinants of gliomagenesis. These include supportive cell types, such as microglia, reactive astrocytes and endothelial cells. Although the role of microglia in Nf1 glioma formation and growth has gained traction, there are fewer data currently available on the important roles that reactive astrocytes and endothelial cells have. Microglia are known in other pathological conditions to increase endothelial cell migration and proliferation as well as to stimulate reactive gliosis. In this manner, microgliainduced neoangiogenesis might create a supportive niche for cancer stem cells, as has been reported for highgrade gliomas (Ludwig et al., 2000; Ren et al., 2004; Calabrese et al., 2007; Charles et al., 2010) , and account for the highly vascular nature of these otherwise relatively benign tumors. Although it is not known what impact Nf1 heterozygosity has on brain endothelial cell function, Nf1 þ /À aortic endothelial cells exhibit increased motility and proliferation and likely participate in establishing a permissive environment for peripheral nerve sheath tumors . Similarly, reactive gliosis resulting from abnormal Nf1 þ /À microglia function might further facilitate the formation of a local microenvironment rich in growth/survival-promoting factors important for glioma formation and maintenance (Giordano et al., 1996; Amankulor et al., 2009) .
It is also worth noting several additional features of the Nf1 þ /À microenvironment. First, it is defined by the presence of cell types and signals unique to a specific region of the brain during a given time of development. In this respect, glial Nf1 loss in the cerebellum occurs in a completely different stromal context than it does in the optic chiasm or brainstem. The gliomagens that facilitate glioma formation and growth as well as the stromagens that promote the establishment of a permissive local environment in one brain region are not equivalent to those present in another brain region. Similarly, the stromagens and gliomagens found in a region at one developmental stage may not be identical to those present later in life. Second, the impact of Nf1 heterozygosity on the evolving tumor microenvironment is unlikely to be the same in all brain locations and at all developmental periods. As different cells in the brain express different molecules in a spatially and temporally regulated fashion, Nf1 heterozygosity may have unique effects on the local brain microenvironment that reflect these regional and developmental conditions. Third, the tumor microenvironment is a dynamic ecosystem, such that the elaboration of specific molecules changes both the cellular and molecular soil in which Nf1-deficient pre-neoplastic/neoplastic cells grow. The panoply of growth/survival factors present at any given time is constantly evolving in response to recruited and modified cell types that, in turn, alter the local environment both spatially and temporally. This state of flux creates a delicately balanced ecological niche as well as a moving target for therapy (Figure 4) .
Another level of system complexity results from the influence of the genomic environment. Although not completely elucidated, genetic modifiers likely change the expression of key stromal growth/survival factors or the activity of specific kinases and enzymes. Although these minor alterations by themselves are not sufficient to result in tumor formation, the confluence of these subtle changes in the correct brain region, at the correct time, and in response to specific cancer-initiating genetic changes could significantly influence gliomagenesis and glioma maintenance.
Finally, as we move into an era of personalized medicine, it will become increasingly important to consider developing therapies that specifically target the neoplastic and non-neoplastic cells in the tumor and to conceptualize tumors as evolving ecosystems. Using this approach, we may be able to design treatments that ultimately result in durable clinical responses. Similarly, should genomic polymorphisms identify at-risk patient subpopulations, the ability to disrupt tumorigenesis by impeding neoplastic/non-neoplastic cell interactions during cancer evolution may be possible. Collectively, the emerging data that derives from the study of Nf1 GEM strains may one day inform both chemoprevention Figure 4 Necessary conditions for NF1-associated gliomagenesis. Nf1 GEM models reveal at least three obligate conditions for brain tumorigenesis. First, Nf1 inactivation must occur in a preneoplastic cell sensitive to Nf1 loss, such as astroglial progenitors of the optic nerve, to result in increased proliferation, survival and migration. Second, a supportive microenvironment is required to facilitate the expansion of the Nf1-deficient glial cells in a spatially and temporally restricted fashion. Third, genomic determinants ('modifier' genes) contribute to tumor susceptibility and growth in currently undetermined ways. and chemotherapy management of cancers of the nervous system.
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